ArticleImmunoTargets and therapy2026
Cryoablation Plus Immune Checkpoint Inhibitors Enhanced Dendritic Cell and T Cell Activation in TNBC Murine Model.
Article in ImmunoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Cryoablation eradicates tumors through repeated freeze-thaw cycles and preserves tumor-associated antigens, triggering inflammatory signals capable of priming anti-tumor immunity, yet its therapeutic potential in triple-negative breast cancer (TNBC) remains largely unexplored. Immune checkpoint inhibitors (ICIs) have shown clinical benefit in TNBC but come with significant immune-related toxicities. Combining cryoablation with ICIs in TNBC may amplify the efficacy of cryoablation, which is significantly less toxic than ICIs, thereby providing opportunities for lowering the doses of ICIs in clinical practice. Here, we investigated the therapeutic impact of cryoablation with ICIs in an orthotopic bilateral murine TNBC model. Methods: Two weeks after tumor induction, primary tumors were cryoablated while the abscopal tumors were not manipulated and represented distant tumors. Twenty-four hours pre- and post-cryoablation, mice received an intra-peritoneal injection of PBS or ICIs (anti-CTLA-4, PD-1, or PD-L1). Tumors, tumor-draining lymph nodes (TdLNs), spleen, and peripheral blood were assessed for immune profiling a week later. Results: Preliminary analyses demonstrated that combining cryoablation with anti-CTLA-4 enhanced T cell activation systemically compared to cryoablation alone or in combination with PD-1/PD-L1 blockade. Notably, relative to cryoablation monotherapy, combination with anti-CTLA-4 increased the frequencies of activated CD4⁺ and CD8⁺ T cells in the abscopal tumors, while also inducing a higher frequency and activation of conventional dendritic cells in the abscopal TdLNs. Conclusion: These results suggest combination of cryoablation with anti-CTLA-4 therapy enhances systemic antitumor immunity by boosting antigen presentation. Our results support further investigation into this combination strategy to prevent tumor recurrence and metastasis while minimizing toxicity of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.